. Author manuscript; available in PMC: 2020 Dec 19.

Published in final edited form as: Horm Res Paediatr. 2019 Dec 19;92(6):347–356. doi: 10.1159/000504802

Table 2.

Medications commonly used in treatment of McCune-Albright syndrome

Indication	Medication	Mechanism of action	Potential adverse effects
Precocious puberty	Letrozole	Aromatase inhibitor	Transient transaminemia
Precocious puberty	Tamoxifen	Estrogen receptor modulator	Endometrial hyperplasia
Hyperthyroidism	Methimazole	Thyroperoxidase inhibitor	Hepatotoxicity, agranulocytosis
Hyperthyroidism	Propylthiouracil	Inhibits thyroperoxidase and 5’-deiodinase	Hepatotoxicity, agranulocytosis
Growth hormone excess	Octreotide; Lanreotide	Somatostatin analog	Cholelithiasis, hepatotoxicity
Growth hormone excess	Pegvisomant	Growth hormone receptor antagonist	Hepatotoxicity
Neonatal hypercortisolism	Metyrapone	11-beta-hydroxylase inhibitor	Hirsutism, hypertension, hyperkalemia
Neonatal hypercortisolism	Ketoconazole	Inhibits cortisol synthesis	Hepatotoxicity, hypogonadism
FGF23-mediated hypophosphatemia	Calcitriol; Alfacalcidiol	Increases dietary calcium absorption and renal tubular calcium reabsorption	Hypercalciuria, hypercalcemia
FGF23-mediated hypophosphatemia	Phosphorus	Supplemental	Gastrointestinal effects